MOHAMAD KASSAR M.D. NPI 1063691830

NPI Details

Mohamad Kassar, M.D. is a hematology and oncology internal medicine in Dyer, IN with 27 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Mohamad Kassar, M.D. NPI is 1063691830. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

1001 CALUMET AVE
DYER, IN
ZIP 46311-596
Phone: (219) 924-8178
Fax: (219) 924-8179

The NPI 1063691830 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, levoleucovorin, not otherwise specified, 0.5 mg (HCPCS:J0641)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood potassium level (HCPCS:84132)
• Phosphatase (enzyme) level, alkaline (HCPCS:84075)
• Blood sodium level (HCPCS:84295)
• Bilirubin level, total (HCPCS:82247)
• Calcium level, total (HCPCS:82310)
• Blood chloride level (HCPCS:82435)
• Albumin (protein) level (HCPCS:82040)
• Liver enzyme (sgpt), level (HCPCS:84460)
• Total protein level, blood (HCPCS:84155)
• Liver enzyme (sgot), level (HCPCS:84450)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, pemetrexed, not otherwise specified, 10 mg (HCPCS:J9305)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, ferric derisomaltose, 10 mg (HCPCS:J1437)
• Blood creatinine level (HCPCS:82565)
• Urea nitrogen level to assess kidney function, quantitative (HCPCS:84520)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Blood glucose (sugar) level (HCPCS:82947)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Magnesium level (HCPCS:83735)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Folic acid level, serum (HCPCS:82746)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Unclassified drugs (HCPCS:J3490)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Initial hospital observation care per day, typically 70 minutes (HCPCS:99220)
• Injection of drug or substance into vein (HCPCS:96374)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Follow-up observation care per day, typically 35 minutes (HCPCS:99226)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Vitamin d-3 level (HCPCS:82306)

The enumeration date for this NPI number is 10/30/2007 and was last updated on 3/22/2021.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.